ArticleJAMA network open2022
Analysis of Time to Diagnosis and Outcomes Among Adults With Primary Hyperparathyroidism.
Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Patient-reported outcome measures for primary hyperparathyroidism: a systematic review of measurement properties.Health and quality of life outcomes · 2024Pooled it
- Increasing incidence and prevalence of biochemically confirmed primary hyperparathyroidism in Stockholm, 2006-2020.The Journal of clinical endocrinology and metabolism · 2026Article
- Utility of albumin-adjusted calcium and calcium‒phosphorus difference in screening for primary hyperparathyroidism.BMC endocrine disorders · 2026Article
- Evaluation of Readability in Patient Education Materials for Primary Hyperparathyroidism.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Use and Implications of the Fracture Risk Assessment Tool in Primary Hyperparathyroidism.JAMA network open · 2026Article
- Should diabetes be considered for curative surgery in primary hyperparathyroidism?Gland surgery · 2026Article
- Low forearm bone density as a clue to suspect primary hyperparathyroidism in postmenopausal women with osteoporosis: a retrospective study.Archives of osteoporosis · 2026Article
- Ectopic parathyroid adenomas in primary hyperparathyroidism: anatomical classifications, localization strategies, and case series.International journal of surgery (London, England) · 2026Article
- Demographic Disparities in Diagnosis and Treatment of Anxiety and Depressive Disorders in Head and Neck Cancer Survivors.Head & neck · 2025Article
- The Landmark Series: Management of Primary Hyperparathyroidism.Annals of surgical oncology · 2025Review
- Impact of intraoperative intact PTH monitoring on reoperation rates and surgical success in primary hyperparathyroidism.BMC endocrine disorders · 2025Article
- An Analysis of Primary Hyperparathyroidism in Association with Depression or Anxiety.Diseases (Basel, Switzerland) · 2025Review
- Opportunistic Assessment for Parathyroid Adenoma on CT: A Retrospective Cohort Study Evaluating Primary Hyperparathyroidism-Associated Morbidity Over 10 Years of Follow-Up.AJR. American journal of roentgenology · 2025Article
- Precision stratified treatment of primary hyperparathyroidism based on multilevel emerging biomarkers.Frontiers in endocrinology · 2025Review
- Severe consequences of uncontrolled tertiary hyperparathyroidism in a limited resources setting: a case report.Frontiers in nephrology · 2025Article
- Opportunities to improve the diagnosis and treatment of primary hyperparathyroidism: retrospective cohort study.Gland surgery · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Importance: Despite access to routine laboratory evaluation, primary hyperparathyroidism (PHP) remains underdiagnosed and undertreated. Objective: To determine the consequences associated with missed diagnoses and prolonged time to diagnosis and treatment of PHP. Design, Setting, and Participants: This is a retrospective cohort study of patients older than 40 years with 2 instances of hypercalcemia during 2010 to 2020 and 3 years of follow-up. Patients were recruited from 63 health care organizations in the TriNetX Research Network. Data analysis was performed from January 2010 to September 2020. Exposures: Elevated serum calcium. Main Outcomes and Measures: Existing symptoms and diagnoses associated with PHP (osteoporosis, fractures, urolithiasis, major depressive disorder, anxiety, hypertension, gastroesophageal reflux disease, malaise or fatigue, joint pain or myalgias, constipation, insomnia, polyuria, weakness, abdominal pain, headache, nausea, amnesia, and gallstones) compared in patients deemed high-risk and without a diagnosis and matched controls, and those who experienced times from documented hypercalcemia to diagnosis and diagnosis to treatment within or beyond 1 year. Results: There were 135 034 patients analyzed (96 554 women [72%]; 28 892 Black patients [21%] and 88 010 White patients [65%]; 3608 Hispanic patients [3%] and 98 279 non-Hispanic patients [73%]; mean [SD] age, 63 [10] years). Two groups without a documented diagnosis of PHP were identified as high risk: 20 176 patients (14.9%) with parathyroid hormone greater than or equal to 50 pg/mL and 24 905 patients (18.4%) with no parathyroid hormone level obtained or recorded explanation for hypercalcemia. High-risk patients experienced significantly increased rates of all associated symptoms and diagnoses compared with matched controls. Just 9.7% of those with hypercalcemia (13 136 patients) had a diagnosis of PHP. Compared with individuals who received a diagnosis within 1 year of hypercalcemia, those whose workup exceeded 1 year had significantly increased rates of major depressive disorder, anxiety, hypertension, gastroesophageal reflux disease, malaise or fatigue, joint pain or myalgias, polyuria, weakness, abdominal pain, and headache at 3 years. The rate of osteoporosis increased from 17.1% (628 patients) to 25.4% (935 patients) over the study period in the group with delayed diagnosis. Among those with a diagnosis, 5280 patients (40.2%) underwent parathyroidectomy. Surgery beyond 1 year of diagnosis was associated with significantly increased rates of osteoporosis and hypertension at 3 years after diagnosis compared with those treated within 1 year. Conclusions and Relevance: Many patients were at high risk for PHP without a documented diagnosis. Complications in these patients, as well as those who received a diagnosis after prolonged workup or time to treatment, resulted in patient harm. System-level interventions are necessary to ensure proper diagnosis and prompt treatment of PHP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.